Global CEO, Apollomics
Venture Partner, OrbiMed
Guo-Liang Yu, Ph.D., is a Venture Partner with OrbiMed. Dr. Yu is currently the Executive Chairman of Crown Biosicence Inc., a leading oncology platform company in China. Previously he was Chairman and CEO of Epitomics Inc., an antibody company acquired by Abcam for $170 million. Dr. Yu was a Senior V.P. at Mendel Biotechnology Inc. and a Senior Scientist at Human Genome Sciences Inc., where he contributed to the discovery of BLys, the target for lupus antibody-drug Benlysta.
Dr. Yu obtained his Ph.D. from the University of California Berkeley and was trained at Harvard Medical School as a postdoctoral fellow. He has co-authored 40 peer-reviewed scientific articles and is also a co-inventor of more than 200 patents.
Dr. Yu serves on the boards of several professional organizations including BayHelix, National Foundation of Cancer Research and the Chinese Biopharmaceutical Association.